| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 34 | 2024 | 935 | 5.720 |
Why?
|
| MicroRNAs | 8 | 2022 | 426 | 2.780 |
Why?
|
| Transcription Factors | 8 | 2021 | 681 | 2.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2022 | 807 | 1.970 |
Why?
|
| Prostate | 7 | 2024 | 154 | 1.290 |
Why?
|
| Breast Neoplasms | 8 | 2022 | 1502 | 1.020 |
Why?
|
| Cell Line, Tumor | 26 | 2023 | 2231 | 0.940 |
Why?
|
| Prostatic Hyperplasia | 1 | 2024 | 34 | 0.920 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2023 | 12 | 0.900 |
Why?
|
| Male | 42 | 2024 | 20025 | 0.900 |
Why?
|
| Cell Nucleus | 3 | 2014 | 366 | 0.880 |
Why?
|
| Humans | 61 | 2024 | 37093 | 0.880 |
Why?
|
| Cell Movement | 5 | 2016 | 571 | 0.870 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2023 | 93 | 0.840 |
Why?
|
| Cadherins | 6 | 2016 | 90 | 0.740 |
Why?
|
| Neoplasm Metastasis | 8 | 2021 | 219 | 0.720 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 213 | 0.680 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2010 | 33 | 0.630 |
Why?
|
| Proteomics | 4 | 2022 | 325 | 0.600 |
Why?
|
| Receptors, Androgen | 1 | 2018 | 126 | 0.590 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 14 | 0.580 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 34 | 0.540 |
Why?
|
| Cell Proliferation | 10 | 2021 | 1198 | 0.520 |
Why?
|
| Antigens, CD | 2 | 2016 | 121 | 0.520 |
Why?
|
| Epithelial Cells | 4 | 2017 | 384 | 0.520 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 78 | 0.520 |
Why?
|
| Cell Adhesion | 4 | 2016 | 212 | 0.520 |
Why?
|
| Neoplasms | 6 | 2023 | 1103 | 0.510 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 111 | 0.490 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 83 | 0.480 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 29 | 0.470 |
Why?
|
| Neoplasm Invasiveness | 6 | 2016 | 251 | 0.460 |
Why?
|
| Mice | 15 | 2024 | 5913 | 0.460 |
Why?
|
| Cell Lineage | 1 | 2013 | 90 | 0.430 |
Why?
|
| Antineoplastic Agents | 5 | 2014 | 803 | 0.420 |
Why?
|
| Apoptosis | 9 | 2017 | 1398 | 0.410 |
Why?
|
| DNA Methylation | 3 | 2022 | 325 | 0.400 |
Why?
|
| Peptides | 3 | 2023 | 320 | 0.400 |
Why?
|
| Dioxoles | 5 | 2012 | 6 | 0.390 |
Why?
|
| Telomerase | 1 | 2011 | 44 | 0.390 |
Why?
|
| Animals | 20 | 2024 | 15081 | 0.380 |
Why?
|
| Isoquinolines | 5 | 2012 | 45 | 0.380 |
Why?
|
| Glycoproteins | 1 | 2011 | 106 | 0.380 |
Why?
|
| Duffy Blood-Group System | 2 | 2021 | 4 | 0.370 |
Why?
|
| Hepatocytes | 2 | 2007 | 75 | 0.350 |
Why?
|
| Epigenesis, Genetic | 3 | 2024 | 219 | 0.350 |
Why?
|
| Receptors, Cell Surface | 2 | 2021 | 144 | 0.340 |
Why?
|
| Kidney Transplantation | 2 | 2020 | 86 | 0.330 |
Why?
|
| Noscapine | 3 | 2014 | 11 | 0.320 |
Why?
|
| Female | 18 | 2024 | 20969 | 0.320 |
Why?
|
| Neoplasm Transplantation | 4 | 2021 | 122 | 0.320 |
Why?
|
| Peptide Fragments | 1 | 2010 | 308 | 0.320 |
Why?
|
| Mutation | 2 | 2022 | 1095 | 0.300 |
Why?
|
| Signal Transduction | 10 | 2022 | 1908 | 0.300 |
Why?
|
| RNA, Messenger | 3 | 2024 | 1207 | 0.300 |
Why?
|
| Bioreactors | 1 | 2007 | 21 | 0.290 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 103 | 0.280 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 190 | 0.280 |
Why?
|
| Flow Cytometry | 3 | 2016 | 399 | 0.270 |
Why?
|
| Healthcare Disparities | 3 | 2022 | 494 | 0.270 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2021 | 85 | 0.260 |
Why?
|
| Mice, Nude | 5 | 2021 | 337 | 0.260 |
Why?
|
| Epidermal Growth Factor | 2 | 2018 | 68 | 0.260 |
Why?
|
| Receptors, Calcitriol | 2 | 2023 | 69 | 0.260 |
Why?
|
| Hormone Antagonists | 1 | 2005 | 14 | 0.260 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 65 | 0.250 |
Why?
|
| Middle Aged | 8 | 2021 | 10129 | 0.240 |
Why?
|
| Axonemal Dyneins | 1 | 2024 | 6 | 0.240 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2024 | 6 | 0.240 |
Why?
|
| Protein Transport | 3 | 2014 | 302 | 0.240 |
Why?
|
| Coculture Techniques | 3 | 2010 | 101 | 0.230 |
Why?
|
| Adenocarcinoma | 3 | 2010 | 251 | 0.230 |
Why?
|
| Cyclodextrins | 2 | 2014 | 10 | 0.230 |
Why?
|
| Drug Delivery Systems | 3 | 2017 | 202 | 0.230 |
Why?
|
| Trans Fatty Acids | 1 | 2023 | 5 | 0.230 |
Why?
|
| Gallium Radioisotopes | 1 | 2023 | 2 | 0.230 |
Why?
|
| Bleomycin | 1 | 2023 | 20 | 0.220 |
Why?
|
| Living Donors | 2 | 2020 | 15 | 0.220 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2023 | 36 | 0.220 |
Why?
|
| Aged | 5 | 2016 | 6741 | 0.220 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2024 | 94 | 0.220 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 358 | 0.200 |
Why?
|
| Alabama | 2 | 2020 | 51 | 0.200 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 75 | 0.200 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 29 | 0.200 |
Why?
|
| Endonucleases | 1 | 2021 | 20 | 0.200 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2021 | 4 | 0.190 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 4 | 0.190 |
Why?
|
| DNA Repair | 1 | 2022 | 188 | 0.190 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 356 | 0.190 |
Why?
|
| Immunotherapy | 1 | 2021 | 95 | 0.180 |
Why?
|
| Databases, Genetic | 2 | 2021 | 93 | 0.180 |
Why?
|
| Vitamin D | 1 | 2022 | 196 | 0.180 |
Why?
|
| Donor Selection | 1 | 2020 | 7 | 0.180 |
Why?
|
| Patient Advocacy | 1 | 2020 | 21 | 0.180 |
Why?
|
| Nanoparticles | 2 | 2017 | 318 | 0.180 |
Why?
|
| Green Fluorescent Proteins | 2 | 2013 | 208 | 0.170 |
Why?
|
| Quality of Life | 1 | 2024 | 481 | 0.170 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2020 | 35 | 0.170 |
Why?
|
| Glycolysis | 2 | 2016 | 68 | 0.170 |
Why?
|
| Cytokines | 1 | 2023 | 602 | 0.170 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 20 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 178 | 0.170 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 275 | 0.170 |
Why?
|
| Stromal Cells | 2 | 2011 | 49 | 0.170 |
Why?
|
| United States | 5 | 2023 | 4223 | 0.160 |
Why?
|
| Health Services Accessibility | 2 | 2022 | 560 | 0.160 |
Why?
|
| Behavioral Research | 1 | 2019 | 39 | 0.160 |
Why?
|
| Chemokines | 1 | 2019 | 97 | 0.160 |
Why?
|
| Minority Health | 1 | 2019 | 88 | 0.160 |
Why?
|
| Quinazolines | 1 | 2018 | 33 | 0.160 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2017 | 13 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 767 | 0.150 |
Why?
|
| Minority Groups | 2 | 2022 | 596 | 0.150 |
Why?
|
| Gene Silencing | 1 | 2018 | 151 | 0.150 |
Why?
|
| Ferric Compounds | 1 | 2017 | 51 | 0.150 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 42 | 0.140 |
Why?
|
| Serine Endopeptidases | 1 | 2017 | 38 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 128 | 0.140 |
Why?
|
| Adult | 4 | 2019 | 11712 | 0.140 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1130 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 643 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2016 | 77 | 0.140 |
Why?
|
| Proteome | 1 | 2017 | 144 | 0.140 |
Why?
|
| Microscopy, Fluorescence | 3 | 2021 | 252 | 0.140 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 76 | 0.130 |
Why?
|
| Autoantibodies | 1 | 2016 | 103 | 0.130 |
Why?
|
| Cell Communication | 2 | 2007 | 97 | 0.130 |
Why?
|
| Galactans | 1 | 2014 | 2 | 0.130 |
Why?
|
| Mannans | 1 | 2014 | 3 | 0.130 |
Why?
|
| Plant Gums | 1 | 2014 | 7 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 502 | 0.120 |
Why?
|
| Microspheres | 1 | 2014 | 49 | 0.120 |
Why?
|
| Mice, SCID | 2 | 2011 | 150 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 623 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2019 | 400 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2014 | 99 | 0.120 |
Why?
|
| Phenotype | 2 | 2014 | 689 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 76 | 0.120 |
Why?
|
| Keratin-14 | 1 | 2013 | 1 | 0.110 |
Why?
|
| Keratin-5 | 1 | 2013 | 8 | 0.110 |
Why?
|
| Integrases | 1 | 2013 | 26 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 515 | 0.110 |
Why?
|
| Ghana | 2 | 2023 | 32 | 0.110 |
Why?
|
| Sex Factors | 1 | 2016 | 898 | 0.110 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 578 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2021 | 189 | 0.110 |
Why?
|
| Subcellular Fractions | 1 | 2012 | 77 | 0.110 |
Why?
|
| Caspase 3 | 2 | 2010 | 207 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 481 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2007 | 1618 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 59 | 0.100 |
Why?
|
| Ipomoea batatas | 1 | 2011 | 6 | 0.100 |
Why?
|
| Cell Aggregation | 1 | 2011 | 15 | 0.100 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 91 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2013 | 326 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 84 | 0.100 |
Why?
|
| NF-kappa B | 1 | 2014 | 339 | 0.100 |
Why?
|
| Cell Separation | 1 | 2011 | 93 | 0.100 |
Why?
|
| ADAM Proteins | 1 | 2011 | 16 | 0.100 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 617 | 0.100 |
Why?
|
| Plant Leaves | 1 | 2011 | 124 | 0.100 |
Why?
|
| Antitussive Agents | 1 | 2010 | 4 | 0.100 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2010 | 10 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2022 | 2026 | 0.090 |
Why?
|
| Epithelium | 1 | 2011 | 79 | 0.090 |
Why?
|
| Gene Expression | 1 | 2014 | 674 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 1039 | 0.090 |
Why?
|
| Cell Survival | 4 | 2017 | 864 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 626 | 0.090 |
Why?
|
| Tubulin Modulators | 1 | 2010 | 18 | 0.090 |
Why?
|
| Disease Progression | 1 | 2012 | 601 | 0.090 |
Why?
|
| Rats | 2 | 2007 | 3483 | 0.080 |
Why?
|
| Teniposide | 1 | 2008 | 1 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 88 | 0.080 |
Why?
|
| Mesoderm | 1 | 2008 | 70 | 0.080 |
Why?
|
| Endothelial Cells | 2 | 2012 | 308 | 0.080 |
Why?
|
| Lymphoma | 1 | 2008 | 38 | 0.080 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2008 | 48 | 0.080 |
Why?
|
| Tubulin | 1 | 2008 | 88 | 0.070 |
Why?
|
| Liver Circulation | 1 | 2007 | 1 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2011 | 517 | 0.070 |
Why?
|
| Perfusion | 1 | 2007 | 33 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2021 | 194 | 0.070 |
Why?
|
| Rats, Transgenic | 1 | 2007 | 27 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2009 | 409 | 0.070 |
Why?
|
| Equipment Design | 1 | 2007 | 124 | 0.070 |
Why?
|
| Mitochondria | 1 | 2010 | 487 | 0.070 |
Why?
|
| Carcinoma | 1 | 2007 | 96 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 2379 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2005 | 176 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 75 | 0.060 |
Why?
|
| Muscle, Smooth | 1 | 2024 | 58 | 0.060 |
Why?
|
| Calorimetry, Differential Scanning | 2 | 2014 | 30 | 0.060 |
Why?
|
| Fatty Acid Desaturases | 1 | 2023 | 4 | 0.060 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 2 | 2014 | 68 | 0.060 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2024 | 86 | 0.060 |
Why?
|
| Receptors, Estrogen | 1 | 2024 | 156 | 0.050 |
Why?
|
| Systems Biology | 1 | 2022 | 22 | 0.050 |
Why?
|
| Risk Factors | 2 | 2021 | 3562 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2023 | 207 | 0.050 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2023 | 58 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 80 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2023 | 127 | 0.050 |
Why?
|
| Estrogens | 1 | 2024 | 202 | 0.050 |
Why?
|
| Thromboxane B2 | 1 | 2022 | 9 | 0.050 |
Why?
|
| Thromboxane A2 | 1 | 2022 | 20 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 94 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2022 | 149 | 0.050 |
Why?
|
| Chromatin | 1 | 2023 | 169 | 0.050 |
Why?
|
| Endoplasmic Reticulum | 1 | 2022 | 105 | 0.050 |
Why?
|
| Aspirin | 1 | 2022 | 49 | 0.050 |
Why?
|
| Young Adult | 1 | 2012 | 4268 | 0.050 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2021 | 4 | 0.050 |
Why?
|
| Carcinoma, Large Cell | 1 | 2021 | 3 | 0.050 |
Why?
|
| Automation, Laboratory | 1 | 2021 | 3 | 0.050 |
Why?
|
| Internationality | 1 | 2021 | 32 | 0.050 |
Why?
|
| Tumor Escape | 1 | 2021 | 13 | 0.050 |
Why?
|
| Tissue Array Analysis | 1 | 2021 | 67 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2021 | 129 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2021 | 61 | 0.050 |
Why?
|
| Carboxylic Acids | 1 | 2020 | 13 | 0.040 |
Why?
|
| Ghrelin | 1 | 2020 | 13 | 0.040 |
Why?
|
| Alleles | 1 | 2021 | 321 | 0.040 |
Why?
|
| G2 Phase | 2 | 2010 | 29 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2020 | 59 | 0.040 |
Why?
|
| Chromatography, Affinity | 1 | 2020 | 67 | 0.040 |
Why?
|
| Nigeria | 1 | 2019 | 86 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 112 | 0.040 |
Why?
|
| Macrophages | 1 | 2023 | 439 | 0.040 |
Why?
|
| Mitosis | 2 | 2010 | 99 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 80 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2009 | 78 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 730 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2019 | 381 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 739 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 182 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 339 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 325 | 0.040 |
Why?
|
| Focus Groups | 1 | 2019 | 348 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 753 | 0.040 |
Why?
|
| Lung | 1 | 2021 | 446 | 0.040 |
Why?
|
| Research Personnel | 1 | 2019 | 155 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2020 | 421 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 113 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2019 | 169 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2017 | 50 | 0.040 |
Why?
|
| Surface Properties | 1 | 2017 | 130 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 1492 | 0.040 |
Why?
|
| Particle Size | 1 | 2017 | 215 | 0.040 |
Why?
|
| Cell Line | 2 | 2010 | 1354 | 0.040 |
Why?
|
| Endocytosis | 1 | 2017 | 113 | 0.040 |
Why?
|
| Antibodies, Neoplasm | 1 | 2016 | 16 | 0.040 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2016 | 33 | 0.040 |
Why?
|
| Incidence | 1 | 2019 | 922 | 0.040 |
Why?
|
| Cell Death | 1 | 2017 | 267 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2017 | 364 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 935 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2016 | 59 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 1742 | 0.030 |
Why?
|
| Iron | 1 | 2017 | 225 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 260 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 362 | 0.030 |
Why?
|
| beta-Cyclodextrins | 1 | 2014 | 24 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2014 | 45 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 62 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2015 | 53 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2015 | 84 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 196 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2014 | 114 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 539 | 0.030 |
Why?
|
| Paxillin | 1 | 2012 | 6 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2019 | 642 | 0.030 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2012 | 22 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2012 | 57 | 0.030 |
Why?
|
| Centrosome | 1 | 2012 | 28 | 0.030 |
Why?
|
| Solubility | 1 | 2012 | 118 | 0.030 |
Why?
|
| Cell Polarity | 1 | 2012 | 54 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 172 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 133 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 513 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 2721 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2011 | 12 | 0.020 |
Why?
|
| Microtubules | 1 | 2012 | 120 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 928 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 5 | 0.020 |
Why?
|
| Superoxides | 1 | 2011 | 53 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 289 | 0.020 |
Why?
|
| Integrins | 1 | 2011 | 51 | 0.020 |
Why?
|
| Androgens | 1 | 2010 | 89 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 142 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 32 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2009 | 77 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2009 | 92 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2009 | 113 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 259 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 222 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 147 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 444 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 661 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 1518 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 435 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 172 | 0.020 |
Why?
|
| Protein Binding | 1 | 2008 | 972 | 0.020 |
Why?
|